Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.72 |
| ▸ | MC4R | P32245 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | CCR3 | P51677 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744977 | 1.00 | SIGMAR1 (0.72) | SIGMAR1MC4RLMNAPOLBCCR3 | |
| SCHEMBL6740759 | 0.89 | CCR3 (0.69) | SIGMAR1MC4RLMNAPOLBCCR3 | |
| SCHEMBL13632432 | 0.89 | CCR3 (0.69) | SIGMAR1MC4RLMNAPOLBCCR3 | |
| SCHEMBL19170201 | 0.89 | CCR3 (0.69) | SIGMAR1MC4RLMNAPOLBCCR3 | |
| SCHEMBL6659339 | 0.87 | SIGMAR1 (0.86) | SIGMAR1MC4RLMNAPOLBCCR3 | |
| SCHEMBL1244038 | 0.87 | CCR3 (0.72) | SIGMAR1MC4RLMNAPOLBCCR3 | |
| SCHEMBL8723260 | 0.85 | CCR3 (0.70) | SIGMAR1MC4RLMNAPOLBCCR3 | |
| SCHEMBL15800706 | 0.85 | CCR3 (0.70) | SIGMAR1MC4RLMNAPOLBCCR3 | |
| SCHEMBL12040820 | 0.85 | CCR3 (0.70) | SIGMAR1MC4RLMNAPOLBCCR3 | |
| SCHEMBL1415730 | 0.85 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNAPOLBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| EP-2865669-B1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | SAMJIN PHARM CO LTD (KR) | 2021-04-28 | — | — | EP | disclosed |
| EP-3180004-B1 | CANCER THERAPEUTICS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10562890-B2 | Cancer therapeutics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2018089695-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| WO-2017198339-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-23 | — | — | WO | disclosed |
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
| WO-2009000878-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| US-20080293722-A1 | Ion Channel Modulators | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293722-A1 | Ion Channel Modulators | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1606267-B1 | PYRAZINE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PROD INC (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1813616-A2 | Pyrazoloquinolines with immunomodulating activity | Active Biotech AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-7199123-B2 | Pyrazine compounds as transforming growth factor (TGF) compounds | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2005090291-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | SIGMAR1 3622/4885MC4R 2195/4885LMNA 3857/4885 |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | SIGMAR1 3476/4885MC4R 2283/4885LMNA 1902/4885 |
| US-20070060570-A1 | Sulfopyrroles | TYK2, ARSA, SULT2A1 | SIGMAR1 1230/4885MC4R 1385/4885LMNA 4097/4885 |
| US-10562890-B2 | Cancer therapeutics | RUNX1, CBFB, MCL1 | SIGMAR1 3622/4885MC4R 2195/4885LMNA 3857/4885 |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | SIGMAR1 3788/4885MC4R 3850/4885LMNA 2652/4885 |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | SIGMAR1 4116/4885MC4R 4234/4885LMNA 3205/4885 |
| US-20080293722-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | SIGMAR1 2986/4885MC4R 1604/4885LMNA 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.